GB811717A - Improvements in or relating to therapeutic compositions - Google Patents
Improvements in or relating to therapeutic compositionsInfo
- Publication number
- GB811717A GB811717A GB21001/55A GB2100155A GB811717A GB 811717 A GB811717 A GB 811717A GB 21001/55 A GB21001/55 A GB 21001/55A GB 2100155 A GB2100155 A GB 2100155A GB 811717 A GB811717 A GB 811717A
- Authority
- GB
- United Kingdom
- Prior art keywords
- penicillin
- per cent
- amount
- sodium
- dibenzylethylenediamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 229930182555 Penicillin Natural products 0.000 abstract 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract 5
- 229940049954 penicillin Drugs 0.000 abstract 5
- 150000002960 penicillins Chemical class 0.000 abstract 3
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 abstract 2
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 abstract 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract 2
- 229910052783 alkali metal Inorganic materials 0.000 abstract 2
- -1 alkali metal salt Chemical class 0.000 abstract 2
- 239000000872 buffer Substances 0.000 abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 abstract 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 abstract 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 abstract 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 abstract 1
- MJPABTWCPARPBD-UHFFFAOYSA-N acetic acid;n,n'-dibenzylethane-1,2-diamine Chemical compound CC(O)=O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 MJPABTWCPARPBD-UHFFFAOYSA-N 0.000 abstract 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 229960000686 benzalkonium chloride Drugs 0.000 abstract 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 abstract 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 abstract 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 230000000994 depressogenic effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 229960001309 procaine hydrochloride Drugs 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 abstract 1
- 239000001632 sodium acetate Substances 0.000 abstract 1
- 235000017281 sodium acetate Nutrition 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 235000011083 sodium citrates Nutrition 0.000 abstract 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 abstract 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 abstract 1
- 239000001540 sodium lactate Substances 0.000 abstract 1
- 229940005581 sodium lactate Drugs 0.000 abstract 1
- 235000011088 sodium lactate Nutrition 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 235000011008 sodium phosphates Nutrition 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
A therapeutic composition comprises a water-insoluble penicillin salt in finely-divided form, polyvinyl-pyrrolidone in amount from about 0.05 to 2.0 per cent, lecithin in amount from about 0.2 to about 5.0 per cent, a parenterally acceptable water-soluble buffer in amount from about 0.5 to 10 per cent, an alkali metal salt of carboxymethylcellulose in amount from about 0.1 to 3 per cent, all by weight of the penicillin salt, and a preservative. Specified penicillin salts include procaine penicillin, dibenzylethylenediamine penicillin; N-benzyl-N1 - (3 - ethoxy - 4 - hydroxy) - benzylethylenediamine penicillin; 2-chloroprocaine penicillin and N,N1 - di - (4 - methoxybenzyl) - ethylenediamine penicillin. Polyvinylpyrrolidone of average molecular weight 40,000 is preferred. Suitable buffers include sodium citrate, sodium acetate, sodium lactate and alkali metal salts of inorganic acids such as mono- and di-basic sodium phosphates. Specified preservatives include the methyl, propyl and butyl esters of p-hydroxybenzoic acid, sodium bisulphite, and quaternary ammonium compounds such as benzalkonium chloride. A stable polyhydroxy alcohol such as sorbitol or mannitol may also be included. A minor proportion of a solubility depressant (e.g. procaine hydrochloride when procaine penicillin is employed, or dibenzylethylenediamine acetate when dibenzylethylenediamine penicillin is employed) may also be included in the compositions. The dried preparation is suitable for extemporaneous compounding with water to form aqueous suspensions for injection purposes. An example is included.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US811717XA | 1954-07-28 | 1954-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB811717A true GB811717A (en) | 1959-04-08 |
Family
ID=22162533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB21001/55A Expired GB811717A (en) | 1954-07-28 | 1955-07-20 | Improvements in or relating to therapeutic compositions |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB811717A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028032A1 (en) * | 2003-09-18 | 2005-03-31 | Scimed Life Systems, Inc. | Injectable therapeutic formulations |
| US7862552B2 (en) | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
| US7906125B2 (en) | 2003-09-18 | 2011-03-15 | Boston Scientific Scimed, Inc. | Solid or semi-solid therapeutic formulations |
| US8263109B2 (en) | 2005-05-09 | 2012-09-11 | Boston Scientific Scimed, Inc. | Injectable bulking compositions |
-
1955
- 1955-07-20 GB GB21001/55A patent/GB811717A/en not_active Expired
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028032A1 (en) * | 2003-09-18 | 2005-03-31 | Scimed Life Systems, Inc. | Injectable therapeutic formulations |
| US7906125B2 (en) | 2003-09-18 | 2011-03-15 | Boston Scientific Scimed, Inc. | Solid or semi-solid therapeutic formulations |
| US7862552B2 (en) | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
| US8263109B2 (en) | 2005-05-09 | 2012-09-11 | Boston Scientific Scimed, Inc. | Injectable bulking compositions |
| US8753620B2 (en) | 2005-05-09 | 2014-06-17 | Boston Scientific Scimed, Inc. | Injectable bulking compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960007599A (en) | Compositions with stable shelf life and easy water solubility of injectable cephalosporins | |
| US2436184A (en) | Pharmaceutical jelly | |
| GB847570A (en) | Shampoo compositions | |
| GB811717A (en) | Improvements in or relating to therapeutic compositions | |
| US4780465A (en) | Aqueous solution containing a quinolone carboxylic acid | |
| US2498200A (en) | Stabilized thiamin | |
| GB1102011A (en) | Phenol esters of amino acids | |
| US2643998A (en) | Stable antibiotic solutions | |
| US2720482A (en) | Stabilized streptomycin solutions | |
| GB999121A (en) | Repository antimalarial compositions | |
| GB705343A (en) | Improvements in or relating to aqueous suspensions of procaine penicillin | |
| GB797237A (en) | Composition for reducing period of anesthesia | |
| US2556688A (en) | Pharmaceutical methionine composition | |
| GB978485A (en) | Iron preparations for intramuscular injection | |
| GB886094A (en) | Novel diiodo-pyridones and compositions containing them | |
| IE35323L (en) | Tropan-3-ol derivatives | |
| GB816592A (en) | A method for the preparation of stable magnesium solutions of high concentration | |
| KR880007543A (en) | Mammalian antibacterial agent containing cephalosporin derivative | |
| GB639173A (en) | Improvements in or relating to aqueous solutions containing soapless detergents | |
| GB1303906A (en) | ||
| GB1084440A (en) | Improvements in or relating to (2-aminocycloalkyl) hydroquinones and the manufacturethereof | |
| GB770075A (en) | Improvements in or relating to preparation of a fibrinogen product and stable solutions thereof | |
| GB1252993A (en) | ||
| GB871456A (en) | Prevention of caking of common salt | |
| GB964448A (en) | A new or improved cleaning and sterilising composition |